PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 12, 20240 citationsOpen Access

Supplementary Figure 1 from Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies

View Full Paper
AKAlana L. KellerLRLauren T. ReimanODOlivia Perez de

Key Points

Key points are not available for this paper at this time.

Abstract

Multi-epitope CD38-FITC binds CD38 in cells treated with SAR442257.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Keller et al. (2024) studied this question.

synapsesocial.com/papers/68e746dfb6db6435876c00bchttps://doi.org/10.1158/2767-9764.25392864.v1
Ask AI
Helpful
Bookmark
Share
View Full Paper